Journal of Commercial Biotechnology — August 2011 issue now available

The August 2011 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 17, Issue 3

Regional biotechnology – The EU biocluster study
Bernhard Zechendorf

Analyzing United States Prescribing Information to gain insight into FDA-sponsor discussions
Iraj Daizadeh
The United States Prescribing Information (USPI) is a key vehicle for communicating the benefit-risk information of a Food and Drug Administration (FDA) approved prescription drug. The USPI is typically the last step of the drug development process and requires discourse between …

Public–private partnerships in global health
Bryan A Liang
This issue of the Journal of Commercial Biotechnology includes the papers from the seventh Annual San Diego Health Policy Conference, ‘Public–Private Partnerships in Global Health’, held on 25 March 2011. The San Diego Heath Policy Conference is sponsored by the Instit …

New approaches to global health governance: The evolution to public–private partnerships
James Balcius, Thomas E Novotny
Global health issues that transcend geopolitical borders are altering the nature of global health governance. Sovereign nations are more connected than ever and increasingly exposed to trans-border health risks. Traditional global health governance may not account for involvement …

Public–private partnerships in trust-based public health social networking: Connecting organizations for regional disease surveillance (CORDS)
Louise S Greshama, Leslie A Pray, Suwit Wibulpolprasert, Beverly Trayner
We describe a new trust-based global health security initiative known as CORDS: Connecting Organizations for Regional Disease Surveillance. Initiated and managed by the Nuclear Threat Initiative with support of The Rockefeller Foundation, Fondation Mérieux and the Skoll Global T …

Global governance: Promoting biodiversity and protecting indigenous communities against biopiracy
Bryan A Liang
Many potentially useful medicines arise from developing countries’ biodiverse environments as well as from indigenous community knowledge. This bioprospecting has become an important strategy in drug discovery and development. However, global intellectual property rules have re …

Enforcement efforts and partnership with industry: A needed strategy addressing counterfeit drugs
Thomas T Kubic
Despite some law enforcement successes, organizations engaged in counterfeiting continued manufacturing, distributing and selling a wide range of unsafe medicines during the past year. This article will identify some of these successes that were made possible due to a public–pr …

Public–private partnerships in addressing counterfeit medicines: The development of the Partnership for Safe Medicines and the Partnership for Safe Medicines-India
Scott LaGanga
The global drug supply chain has resulted in tremendous vulnerabilities. Despite individual country efforts, both developed and resource-poor countries have experienced tremendous challenges with ensuring safety of the drug supply. In this piece, the formation of a novel public� …

Promoting online drug safety: Using public–private partnerships to deter illicit online drug sales
Timothy K Mackey, Bryan A Liang
Illicit online pharmacies selling counterfeit drugs in a global virtual marketplace remain a critical problem in global health. Yet they continue to operate with little regulation while growing numbers of consumers access the Internet for health information that may lead them to …

Recapping Section 48D (qualifying therapeutic discovery project credit) − Will it be extended?
Peter Wynacht

Trade secrets: At the crossroads of intellectual property and labor and employment law
Roy Salins

Notes from the EU
Gerry Kamstra

For more information, see the Journal of Commercial Biotechnology

Scroll to Top